Highlights

  • Radiopharm Theranostics (ASX:RAD) shares rose about 5.26% to A$0.02, during the afternoon trading session on 13 July 2026.
  • No verified company-specific announcement was identified for 13 July 2026; the move came from a very low share price where small shifts create large percentage swings.
  • Radiopharm develops a pipeline of radiopharmaceuticals for oncology, led by the RAD 101 brain-metastases imaging programme, which reported strong interim concordance data in 2026.
  • The company reported cash of about A$19.2 million at 31 March 2026, down from A$34.5 million, reflecting a high quarterly cash burn.
  • As a pre-revenue biotech, Radiopharm carries clinical, regulatory and funding risks, and future capital raisings could dilute shareholders.

A sharp percentage gain from a very low base

Radiopharm Theranostics Limited (ASX:RAD) was among the firmer movers in the ASX biotechnology cohort on 13 July 2026, its shares rising about 5.26% to A$0.02 according to market data delayed by at least 20 minutes that may since have changed. The move left the clinical-stage radiopharmaceutical company with a market capitalisation of roughly A$67.34 million on the day.

At a share price of two cents, a one-tick move produces a large percentage change, and a stock at such a low absolute price can swing sharply on modest turnover, sentiment or momentum. Radiopharm sits within nuclear medicine, an area attracting growing investor and industry attention as radiopharmaceuticals gain traction in cancer diagnosis and treatment.

What happened to Radiopharm Theranostics shares?

On 13 July 2026, Radiopharm shares settled at A$0.02 in the reference snapshot, up approximately 5.26%, placing RAD among the day's firmer biotechnology performers, though the move was tiny in absolute cents. Radiopharm trades on the ASX under RAD and also has American Depositary Shares on the Nasdaq under RADX, which can behave differently.

Was there a verified catalyst?

Based on the sources reviewed, no specific Radiopharm announcement was identified as being lodged with the ASX on or immediately around 13 July 2026 that would clearly explain the gain. The company's most recent material updates predate that session, concentrated in the first half of 2026 — RAD 101 trial enrolment and strong interim data, RAD 202 dose-escalation progress, early-stage first-patient dosing, and half-year and quarterly reports. Absent a fresh, verified catalyst dated to 13 July 2026, the move most likely reflects the low share price and broader sentiment toward nuclear-medicine and ASX biotech shares; readers should treat a single-session move in a two-cent stock with caution.

What does Radiopharm Theranostics (ASX:RAD) do?

Radiopharm Theranostics is a clinical-stage biotechnology company developing radiopharmaceuticals — medicines that use radioactive isotopes attached to targeting molecules to image or treat disease. Its focus is oncology, spanning both diagnostic imaging agents and therapeutic products that deliver radiation directly to tumours. This dual approach reflects the "theranostics" concept in the company's name: a diagnostic agent helps identify patients whose tumours express a target and a matched therapeutic agent then treats them. As a clinical-stage developer, Radiopharm has no approved product and generates minimal revenue, funding its programmes through cash reserves, partnerships and periodic capital raisings.

Key products, technologies and clinical programs

Radiopharm's most advanced diagnostic asset is RAD 101, an imaging agent developed to help distinguish recurrent brain metastases from treatment effects — a clinically important, difficult distinction. It has been evaluated in a US Phase 2b imaging trial and holds US FDA Fast Track Designation for this use. On the therapeutic side, RAD 202 has been advancing through a Phase 1 dose-escalation trial known as HEAT; RAD 204 is a Phase 1 programme in advanced prostate cancer; and RV-01 is an earlier First-In-Human Phase 1/2a candidate. Radiopharm has built industry relationships, including collaborations referenced with Lantheus Holdings, a radiopharmaceuticals specialist, plus supply arrangements for RAD 101 — relationships that can provide capital, expertise and manufacturing support.

Clinical-development position

Radiopharm made notable clinical progress in the first half of 2026. Its RAD 101 Phase 2b imaging trial in brain metastases reported that around 90% of evaluable patients at an interim analysis achieved concordance with MRI imaging, the primary endpoint; the company completed enrolment during April 2026, with a fuller readout anticipated around mid-2026. On the therapeutic side, RAD 202 was reported generally well tolerated with no dose-limiting toxicities and meaningful tumour uptake, and received a positive data-safety-committee recommendation to advance to a higher dose level; RAD 204 progressed through dose escalation, and RV-01 dosed its first patient early in 2026.

Investors should note the range of development stages: RAD 101 is the most advanced, at Phase 2b in a diagnostic setting, while the therapeutic programmes are earlier, at Phase 1 or First-In-Human. Early and interim data, particularly in small patient numbers, are encouraging signals rather than definitive proof of efficacy and require confirmation in larger studies.

Regulatory and commercial pathway

With no marketed product, Radiopharm's regulatory pathway centres on generating the clinical evidence required to seek future approvals from bodies such as the US FDA. RAD 101's FDA Fast Track Designation is a supportive mechanism intended to facilitate development of therapies for serious conditions, but it is not an approval and does not guarantee the product will reach the market.

Commercially, radiopharmaceuticals present distinctive challenges: they often require specialised manufacturing, isotope supply and distribution logistics because of their radioactive nature and limited shelf life, making industry partnerships particularly important. Any eventual commercialisation would depend on successful later-stage trials, regulatory approval and either partnering or building specialised capability, none of which is assured.

Latest financial position

As a clinical-stage biotech, Radiopharm funds its operations from cash reserves rather than product sales. For the quarter ended 31 March 2026, it reported closing cash of approximately A$19.2 million, down from about A$34.5 million, after net operating cash outflows of around A$14.9 million (figures in Australian dollars for the periods noted). That level of quarterly cash burn is significant relative to the closing balance, and it materially reduced the runway into 2027 the company had earlier described at its half-year results. Radiopharm also received an Australian R&D tax refund of around A$5.9 million, a source of non-dilutive funding.

Given the pace of spending, Radiopharm's cash position is a central issue. As a pre-revenue business, it remains dependent on reserves and potentially future capital raisings that could dilute existing shareholders. Readers seeking current figures should consult Radiopharm's latest Appendix 4C on the ASX.

Market opportunity

The radiopharmaceuticals market has become one of the more closely watched areas in oncology. Radiolabelled diagnostics and therapeutics have gained clinical traction, and large pharmaceutical companies have shown strong interest, underpinning the "nuclear-medicine interest" referenced in the headline. That said, market enthusiasm does not translate into value on its own; Radiopharm must still demonstrate efficacy and safety in later-stage trials, navigate regulatory approval, solve specialised manufacturing challenges, and compete with well-resourced developers.

Recent official announcements

Public records point to several Radiopharm updates in the first half of 2026: January 2026 half-year results; February 2026 first-patient dosing in the RV-01 First-In-Human study; and March–April 2026 interim RAD 101 data, completion of RAD 101 Phase 2b enrolment, RAD 202 data at a major cancer research conference and RAD 202's advance to a higher dose cohort. The company also reported its March 2026 quarterly cash position. No fresh announcement dated specifically to 13 July 2026 was identified in the sources reviewed; investors should consult Radiopharm's official ASX announcements platform for same-day disclosures.

Potential positive considerations

Several factors may be viewed constructively. Radiopharm's RAD 101 programme reported strong interim concordance data in its Phase 2b brain-metastases imaging trial and holds FDA Fast Track Designation, and its therapeutic programmes advanced through early dose-escalation milestones with encouraging safety signals. The company operates in a field attracting significant industry interest, has relationships with established radiopharmaceutical players, and secured a non-dilutive R&D tax refund. These are potential positives, not guarantees; each depends on further clinical validation, regulatory progress and adequate funding.

Main risks and uncertainties

The risks are substantial. Radiopharm is a pre-revenue, clinical-stage biotech with most programmes at Phase 1 or First-In-Human, and early data may not be confirmed in larger trials. Funding risk is especially prominent: the March 2026 quarter's cash outflow of around A$14.9 million reduced the closing balance to about A$19.2 million, implying further capital may be needed before long, and any raising could dilute shareholders. Regulatory approval is never guaranteed, and Fast Track Designation is not an approval. Radiopharmaceuticals also face distinctive manufacturing complexity. At two cents the share price is highly volatile, and biotechnology investment risks are heightened for micro-cap names.

What investors may watch next

Investors may monitor the full RAD 101 Phase 2b data readout and any subsequent regulatory steps, along with dose-escalation and safety updates across the therapeutic programmes. The cash position and funding plans warrant close attention given the burn rate, as do any new partnerships, all subject to clinical, regulatory and commercial outcomes.

A balanced view on Radiopharm Theranostics (ASX:RAD)

Radiopharm Theranostics (ASX:RAD) rose about 5.26% to A$0.02 on 13 July 2026, but the move came from a very low base and, on the evidence reviewed, without a clearly verified same-day catalyst — appearing more consistent with the mechanics of a two-cent stock and broader nuclear-medicine sentiment than a specific corporate development.

Beneath the day's move, Radiopharm offers a genuinely interesting pipeline in a field of rising interest, with encouraging early RAD 101 data and several therapeutic programmes advancing, set against the substantial risks of early-stage evidence, a high cash-burn rate and likely future funding needs. Investors may wish to weigh the promise of its radiopharmaceutical portfolio against the very real biotechnology investment risks, and to treat single-session volatility in a low-priced stock with caution.